Cancer clinical trials in the region Hauts-de-France

341 currently recruiting clinical trials
Region Hauts-de-France
Phase 1 / Phase 2 Lung cancer #NCT06128551
Phase 1b expansion de dose et phase 2 cohortes CBNPC non naïf d'inhibiteurs de KRAS G12C
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Lung cancer Prostate cancer Colon cancer Rectal cancer Liver and bile duct cancer Head and neck cancer #NCT06725758 #2022-503061-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Mesothelium Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses
Required histologic sub types
Hepatocellular carcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Orion Pharma
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06818643 #2024-516817-19-00
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06888921 #2025-521125-33-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy
8 recruiting sites
Compugen Ltd
Phase 1 / Phase 2 Lung cancer #NCT06362252 #2023-509629-36-00
Cohorte 1 (Maintenance)
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
8 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Lymphoma #NCT04669171 #2023-509254-58-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma Marginal zone lymphoma
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Immunotherapy Allogeneic stem cell transplant
1 recruiting site
Entérome
Phase 1 / Phase 2 Lymphoma #NCT04669171 #2023-509254-58-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma Marginal zone lymphoma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Allogeneic stem cell transplant
1 recruiting site
Entérome
Phase 1 / Phase 2 Lymphoma #NCT07018752 #2024-514954-63-00
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 1 / Phase 2 Lung cancer #NCT06448572
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded genetic anomalies
ALK BRAF EGFR HER2 MET RET ROS-1
1 recruiting site
CHU Lille
Not Applicable Liver and bile duct cancer #NCT04935853
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
32 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie